[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Yehui Tan\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":81},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,61],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100594756","phase-2-study-on-optimizing-the-treatment-of-patients-with-acute-myeloid-leukemia-based-on-early-peripheral-blood-minimal-residual-disease-100594756",false,"NCT07023588","Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease","A Multicenter, Open-label, Prospective, Randomized Controlled Study to Optimize the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease","Inclusion Criteria:\n\n1. Newly diagnosed AML patients confirmed by bone marrow morphology and immunophenotyping.\n2. Complete MICM (Morphology, Immunophenotyping, Cytogenetics, Molecular genetics) work-up.\n3. Age ≥ 18 years.\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n5. Day 6 Peripheral Blood Blast Percentage (D6PBBP) ≥ 1%.\n6. Renal function with creatinine clearance ≥ 50 mL\u002Fmin (calculated using the Cockcroft-Gault formula or measured by 24-hour urine collection).\n7. Liver function with Aspartate Aminotransferase (AST) ≤ 2.5 × ULN\\*; Alanine Aminotransferase (ALT) ≤ 2.5 × ULN\\*; Total bilirubin ≤ 1.5 × ULN\\* (\\*Unless considered due to leukemia infiltration).\n8. Patients deemed suitable to receive DA\u002FIA therapy by the investigator.\n9. Signed informed consent form. -\n\nExclusion Criteria:\n\n1. Acute promyelocytic leukemia (APL).\n2. Mixed phenotype acute leukemia (MPAL).\n3. AML patients with known central nervous system (CNS) involvement.\n4. Presence of extramedullary disease (EMD).\n5. Significant hepatic or renal dysfunction exceeding the inclusion criteria limits.\n6. Severe cardiac disease, including congestive heart failure, myocardial infarction, or cardiac dysfunction.\n7. Concurrent active malignancy of other organ systems (patients with a history of cured malignancy may be eligible).\n8. Active tuberculosis or HIV-positive patients.\n9. Concurrent other hematological disorders.\n10. Pregnant or lactating women.\n11. Inability to comprehend or comply with the study protocol.\n12. Hypersensitivity to any component of the drugs involved in the protocol.\n13. Inability to take oral medication or patients with malabsorption syndrome.\n14. Uncontrolled systemic infection.\n15. Prior venetoclax treatment and\u002For current participation in any other study involving investigational agents.","ALL","18 Years",{"count":19,"type":20},70,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","A multicenter, open-label, prospective, randomized controlled study to optimize the treatment of patients with acute myeloid leukemia based on early peripheral blood minimal residual disease",[26],"Acute Myeloid Leukemia (AML)","RECRUITING","2025-08-05",{"date":30,"type":31},"2025-08-08","ACTUAL",{"date":33,"type":31},"2025-06-01",{"date":35,"type":20},"2029-05",{"name":37,"class":38},"Yehui Tan","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":56,"startDateStruct":57,"completionDateStruct":58,"leadSponsor":60,"locationsCount":39},"100592199","phase-3-effectiveness-of-medium-dose-cytarabine-combined-with-venetoclax-for-consolidation-therapy-in-elderly-patients-with-intermediate-to-high-risk-acute-myeloid-leukemia-100592199","NCT06990321","Effectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid Leukemia","A Single-center, Single-arm, Prospective Clinical Study of Intermediate-dose Cytarabine in Combination With Venetoclax for Consolidation Therapy of Middle- and High-risk Acute Myeloid Leukemia in The Elderly","Inclusion Criteria:\n\n1.Age ≥ 60 years and ≤ 75 years, regardless of gender; 2.Diagnosed with AML (acute myeloid leukemia) according to WHO criteria (non-acute promyelocytic leukemia); 3.Risk stratification as intermediate or high risk based on the ELN (2022) guidelines; 4.Expected survival time ≥ 3 months; 5.Not suitable for allogeneic hematopoietic stem cell transplantation; 6.AML patients who achieve remission with morphologic assessment of bone marrow showing no leukemic involvement after induction therapy; 7.Eastern Cooperative Oncology Group Performance Status (ECOG-PS) score of 0-2; 8.Meeting the following laboratory requirements (performed within 7 days prior to treatment):\n\n1. Total bilirubin ≤ 1.5 times the upper limit of normal for the same age group;\n2. AST and ALT ≤ 2.5 times the upper limit of normal for the same age group;\n3. Serum creatinine \\< 2 times the upper limit of normal for the same age group;\n4. Cardiac ejection fraction within normal limits as determined by echocardiogram. 9.Able to comply with the study visit schedule and understand and adhere to all trial protocol requirements; 10.Able to take oral medications.\n\nExclusion Criteria:\n\nSubjects who meet any of the following criteria shall not be included in this study:\n\n1. Allergic to any drugs included in the trial protocol or drugs with a chemical structure similar to the investigational drug.\n2. Chemotherapy intolerance assessed by Ferrara 2013 criteria prior to enrollment.\n3. Hematologic relapse (bone marrow blasts or immature cells exceed 5%).\n4. Simultaneous diagnosis of other malignant tumors in organs (requiring treatment).\n5. Known or suspected drug abuse or alcohol dependence.\n6. Mental illness or any condition that prevents obtaining informed consent, or inability to comply with the study treatment and examination requirements.\n7. Liver dysfunction (total bilirubin \\>1.5×ULN, ALT\u002FAST \\>2.5×ULN, or liver-involved patients with ALT\u002FAST \\>5×ULN), kidney dysfunction (serum creatinine \\>1.5×ULN).\n8. Active heart disease, defined as one or more of the following:\n\n1\\) History of uncontrolled or symptomatic angina. 2) Myocardial infarction within 6 months prior to enrollment. 3) History of arrhythmias requiring drug treatment or with severe clinical symptoms.\n\n4\\) Uncontrolled or symptomatic congestive heart failure (\\>NYHA class 2). 5) Ejection fraction below the lower limit of normal. 9.Participation in another clinical trial within 30 days. 10.Active infection. 11.The investigator deems the subject unfit for participation in this trial.","60 Years","75 Years",{"count":50,"type":20},68,[52],"PHASE3","A Single-center, Single-arm, Prospective Clinical Study of Intermediate-dose Cytarabine in Combination with Venetoclax for Consolidation Therapy of Middle- and High-risk Acute Myeloid Leukemia in the Elderly",[26,55],"Elderly",{"date":30,"type":31},{"date":33,"type":31},{"date":59,"type":20},"2026-12-31",{"name":37,"class":38},{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":4,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":68,"targetDuration":4,"studyType":21,"phases":70,"briefSummary":71,"conditions":72,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":75,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":39},"100596570","phase-2-clinical-study-of-venetoclax-combined-with-azacitidine-as-bridging-therapy-prior-to-hematopoietic-stem-cell-transplantation-in-patients-with-higher-risk-myelodysplastic-syndromes-100596570","NCT07047183","Clinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk Myelodysplastic Syndromes","A Single-Arm, Prospective Clinical Study of Venetoclax Combined With Azacitidine Followed by Bridging Transplantation in Patients With High-Risk Myelodysplastic Neoplasms With Increased Blasts 2 (MDS-IB2)","Inclusion Criteria:\n\n1. Newly diagnosed MDS confirmed by morphological and immunophenotypic analysis of bone marrow；\n2. Age ≥18 years, any gender；\n3. Bone marrow blasts ≥10%；\n4. IPSS-R score \\>4.5；\n5. ECOG performance status 0-2；\n6. Scheduled for allogeneic hematopoietic stem cell transplantation (allo-HSCT)；\n7. Adequate major organ function：\n\n   * Cardiac: LVEF ≥50%\n   * Hepatic: Bilirubin ≤1.5×ULN\n   * AST\u002FALT ≤2.5×ULN\n   * Renal: Creatinine clearance ≥60 mL\u002Fmin；\n8. Written informed consent provided by the patient or legally authorized representative.\n\nExclusion Criteria:\n\n1. Extramedullary disease involvement；\n2. Hypersensitivity to any study drugs；\n3. Clinically significant hepatic\u002Frenal dysfunction exceeding inclusion thresholds；\n4. Severe cardiac disease, including congestive heart failure, myocardial infarction, and cardiac insufficiency;\n5. Concurrent malignant tumors of other organs, which can be enrolled if previously cured;\n6. Active tuberculosis or HIV infection;\n7. Concomitant hematologic disorders;\n8. Pregnancy or lactation;\n9. Inability to comply with protocol requirements;\n10. Concurrently participating in other clinical studies.",{"count":69,"type":20},46,[23],"A Single-Arm, Prospective Clinical Study of Venetoclax Combined with Azacitidine Followed by Bridging Transplantation in Patients with High-Risk Myelodysplastic Neoplasms with Increased Blasts 2 (MDS-IB2)",[73,74],"Myelodysplastic Neoplasms","Transplantation",{"date":30,"type":31},{"date":77,"type":31},"2025-07-01",{"date":79,"type":20},"2029-06-30",{"name":37,"class":38},""]